Cohance Lifesciences Limited — Updates, 13-08-2025: Press Release

Cohance Lifesciences reported robust Q1 financial results, with revenue at ₹549.3 Cr, up 13% YoY, or over 25% excluding destocking impact. Gross margins expanded to 73.0%. Adjusted EBITDA stood at ₹131.4 Cr. Niche technology revenues now exceed 20%, driven by strong growth in Pharma CDMO, Specialty Chemicals, and API+. Strategic moves include a USD 10M bioconjugation suite and a ₹23.0 Cr oligonucleotide facility on track. The company secured new orders, saw a partner's program gain USFDA approval, expanded its customer base, and appointed a new CDMO CEO, strengthening its leadership.